Dose Response in TRT for ES-SCLC.
A-Survival all thoracic radiotherapy patients < 45 Gy vs. ≥45 Gy.
B-Survival thoracic radiotherapy patients after 12 weeks of chemotherapy < 45 Gy vs. ≥45 Gy.
C-Survival all thoracic radiotherapy patients low vs. intermediate vs. high dose.
D-Survival thoracic radiotherapy patients after 12 weeks of chemotherapy low vs. intermediate vs. high dose.